Compass Therapeutics (CMPX) Retained Earnings (2018 - 2026)
Compass Therapeutics recorded quarterly Retained Earnings of -$449.5 million in Q1 2026, down 160631.79% quarter-over-quarter from $280000.0 in Q4 2025, and down 236673.16% year-over-year from N/an in Q1 2025.
Compass Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$449.5 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 236673.16% year-over-year to -$449.5 million; the TTM figure through Mar 2026 stood at -$449.5 million (down 236673.16% YoY), while the FY2025 annual figure was $280000.0, up 33.33% from the prior year.
- Retained Earnings came in at -$449.5 million for Q1 2026 at Compass Therapeutics, down from $280000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $486000.0 in Q3 2024 to a low of -$449.5 million in Q1 2026.
- A 5-year average of -$155.8 million and a median of -$512000.0 in 2022 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 311.11% in 2025 and fell as far as 440775.82% in 2025.
- Compass Therapeutics' Retained Earnings stood at -$272.8 million in 2022, then decreased by 15.58% to -$315.3 million in 2023, then surged by 100.07% to $210000.0 in 2024, then soared by 33.33% to $280000.0 in 2025, then slumped by 160631.79% to -$449.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$449.5 million, $280000.0, and -$415.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -449.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -449.49 Mn |
| Dec 31, 2025 | 280,000.00 |
| Sep 30, 2025 | -415.46 Mn |
| Jun 30, 2025 | -401.20 Mn |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | 210,000.00 |
| Sep 30, 2024 | 486,000.00 |
| Jun 30, 2024 | -91,000.00 |
| Mar 31, 2024 | -90,000.00 |
| Dec 31, 2023 | -315.31 Mn |
| Sep 30, 2023 | -430,000.00 |
| Jun 30, 2023 | -291.93 Mn |
| Mar 31, 2023 | -146,000.00 |
| Dec 31, 2022 | -272.81 Mn |
| Sep 30, 2022 | -261.22 Mn |
| Jun 30, 2022 | -512,000.00 |
| Mar 31, 2022 | -240.75 Mn |
| Sep 30, 2021 | -220.61 Mn |
| Mar 31, 2021 | -158.83 Mn |
| Dec 31, 2020 | -151.41 Mn |
| Sep 30, 2020 | -143.02 Mn |
| Jun 30, 2020 | -133.87 Mn |
| Mar 31, 2020 | -108,572.00 |
| Dec 31, 2019 | -121.91 Mn |
| Sep 30, 2019 | -90,954.00 |
| Jun 30, 2019 | -82,551.00 |
| Mar 31, 2019 | -71,089.00 |
| Dec 31, 2018 | -62,224.00 |
| Sep 30, 2018 | -52,082.00 |
| Jun 30, 2018 | -43,526.00 |
| Mar 31, 2018 | -35,052.00 |